Remove Antibody Remove Bacterium Remove Immune Response
article thumbnail

Shot in the arm for Affinivax as it challenges Pfizer’s Prevnar

pharmaphorum

The shot also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype, so could potentially provide protection against an even broader range.

article thumbnail

New Research Shows IBS Symptoms May be Caused by Gut Infections

XTalks

While diseases like celiac are associated with inappropriate activation of the immune system triggered by food antigens, this is not the case in IBS. In a normal, healthy intestine, foods do not trigger immune responses and so in a patient with IBS, something else must activate the response. Mouse and Human Studies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GSK bolsters vaccines division with $3.3bn swoop on Affinivax

pharmaphorum

With ASP3772, GSK could offer a shot with broader coverage of pneumococcal serotypes than any of its rivals, and which also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype.

article thumbnail

GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.

The Pharma Data

” In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. The bacterium Streptococcus pneumoniae causes pneumococcal disease. pneumoniae invasive disease and pneumonia in adults 50 years and above.

article thumbnail

GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.

The Pharma Data

In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. The bacterium Streptococcus pneumoniae causes pneumococcal disease. pneumoniae invasive disease and pneumonia in adults 50 years and above. Pneumococcal disease.

article thumbnail

Medicago’s Plant-Based COVID-19 Vaccine Enters Human Trials

XTalks

Interim results of the trial show that all participants developed an antibody response after two doses of the COVID-19 adjuvanted vaccine candidate. We also observed that the antibody levels were higher after vaccination than those observed in convalescent sera from people who recovered from the disease,” said Landry.